AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27469482 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP guided therapy (goal NT‐proBNP <1000 pg/mL)
Number of subjects: 151
Study 25350223 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 256
Study 24023318 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11/S‐1 (IRIS) regimen
Number of subjects: 0
Study 24023318 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU)/l‐leucovorin (LV)/CPT‐11 (FOLFIRI) regimen
Number of subjects: 0
Study 21940574 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual gastroscopy with MPR images
Number of subjects: 175
Study 21940574 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic ultrasound
Number of subjects: 175
Study 21940574 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual gastroscopy alone
Number of subjects: 175
Study 18177441 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (K) during blood test stick (BT) procedure
Number of subjects: 30
Study 18177441 — intervention group
Group type: COMPARATOR
Intervention: Standard within-crib care (C) during blood test stick (BT) procedure
Number of subjects: 30
Study 18177441 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (K) during no blood test stick (W) procedure
Number of subjects: 30
Study 18177441 — intervention group
Group type: COMPARATOR
Intervention: Standard within-crib care (C) during no blood test stick (W) procedure
Number of subjects: 30
Study 16276071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-like meal (45% fat, 1,000 Kcal, monounsaturated 61% of fat)
Number of subjects: 8
Study 16276071 — intervention group
Group type: COMPARATOR
Intervention: Western-like meal (saturated 57% of fat)
Number of subjects: 8
Study 12975721 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, dihydropyridine calcium antagonists
Number of subjects: 0
Study 12975721 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 12975721 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 0
Study 12975721 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple antihypertensive drugs
Number of subjects: 0
Study 10731173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised weight reduction programme including 8 week very low energy diet
Number of subjects: 38
Study 9380472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension 15 mg/kg
Number of subjects: 17
Study 1390607 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation combined with albendazole
Number of subjects: 2268
Study 1390607 — intervention group
Group type: COMPARATOR
Intervention: Albendazole only (Control)
Number of subjects: 2268
Study 4020587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol education programs with a credible communicator and low fear appeal
Number of subjects: 0
Study 4020587 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol education programs
Number of subjects: 0
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Average estimated tumor percentage
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured total tumor length
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Average calculated tumor percentage
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest tumor length
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Greatest tumor percentage
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Average tumor percentage of all biopsies
Number of subjects: 1031
Study 31904279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated tumor length
Number of subjects: 1031
Study 29332445 — intervention group
Group type: EXPERIMENTAL
Intervention: 70° stylet
Number of subjects: 162
Study 29332445 — intervention group
Group type: COMPARATOR
Intervention: 90° stylet
Number of subjects: 162
Study 27617373 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite onlays (IRC onlay)
Number of subjects: 50
Study 27617373 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns (SSC)
Number of subjects: 50
Study 24824648 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose)
Number of subjects: 64
Study 24824648 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose plus booster)
Number of subjects: 64
Study 22285435 — intervention group
Group type: EXPERIMENTAL
Intervention: Remember (R) instructions
Number of subjects: 17
Study 22285435 — intervention group
Group type: EXPERIMENTAL
Intervention: Forget (F) instructions
Number of subjects: 17
Study 22285435 — intervention group
Group type: COMPARATOR
Intervention: Neutral images
Number of subjects: 17
Study 22285435 — intervention group
Group type: COMPARATOR
Intervention: Negative images
Number of subjects: 17
Study 20624243 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LENS intervention
Number of subjects: 34
Study 20624243 — intervention group
Group type: COMPARATOR
Intervention: Sham LENS intervention
Number of subjects: 34
Study 18398528 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone based asthma management
Number of subjects: 0
Study 18398528 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 15992524 — intervention group
Group type: EXPERIMENTAL
Intervention: SGAs (risperidone and ziprasidone)
Number of subjects: 19
Study 15992524 — intervention group
Group type: COMPARATOR
Intervention: FGA (haloperidol)
Number of subjects: 19
Study 15992524 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 19
Study 12056293 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d sulfasalazine
Number of subjects: 70
Study 12056293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12056293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 70
Study 10692750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (750 mg b.d.)
Number of subjects: 145
Study 10692750 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (875/125 mg b.d.)
Number of subjects: 145
Study 8726764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 62
Study 8726764 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation
Number of subjects: 62
Study 1768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase testing
Number of subjects: 24
Study 1768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase testing
Number of subjects: 24
Study 1768223 — intervention group
Group type: COMPARATOR
Intervention: Natural menstrual cycle
Number of subjects: 24
Study 1768223 — intervention group
Group type: COMPARATOR
Intervention: Low-dose estrogen oral contraceptive pills
Number of subjects: 24
Study 1768223 — intervention group
Group type: EXPERIMENTAL
Intervention: First test in follicular phase
Number of subjects: 24
Study 1768223 — intervention group
Group type: EXPERIMENTAL
Intervention: First test in luteal phase
Number of subjects: 24
Study 6790206 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg, i.v. administration)
Number of subjects: 25
Study 6790206 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle control
Number of subjects: 25
Study 30902674 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Resistance Training (ERT)
Number of subjects: 20
Study 30902674 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 28342007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with LED 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Number of subjects: 79
Study 28342007 — intervention group
Group type: COMPARATOR
Intervention: Control group received phototherapy with broadband 580-900 nm and power density 0.72 J/cm2
Number of subjects: 79
Study 28342007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with LED
Number of subjects: 79
Study 26121830 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 188
Study 26121830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid therapy
Number of subjects: 188
Study 26121830 — intervention group
Group type: EXPERIMENTAL
Intervention: Postauricular steroid therapy
Number of subjects: 188
Study 23126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional writing condition
Number of subjects: 748
Study 23126551 — intervention group
Group type: COMPARATOR
Intervention: Non-emotional writing condition
Number of subjects: 748
Study 23126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressors
Number of subjects: 748
Study 23126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensive high-anxious individuals
Number of subjects: 748
Study 23126551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-anxious individuals
Number of subjects: 748
Study 21338816 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk powder diet
Number of subjects: 10
Study 21338816 — intervention group
Group type: COMPARATOR
Intervention: Soybean concentrate diet
Number of subjects: 10
Study 19805701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral naltrexone, 50 mg/d for 6 months (plus placebo implants)
Number of subjects: 70
Study 19805701 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone implant, single dose of 2.3 g (plus placebo tablets)
Number of subjects: 70
Study 17598625 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic plus resistance training for 16 weeks)
Number of subjects: 73
Study 17598625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 73
Study 15199090 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + para-aortic nodal dissection
Number of subjects: 523
Study 15199090 — intervention group
Group type: COMPARATOR
Intervention: D2 lymphadenectomy
Number of subjects: 523
Study 15199090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D2 and D2 + para-aortic)
Number of subjects: 523
Study 11498313 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐atracurium
Number of subjects: 39
Study 11498313 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 39
Study 11498313 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 39
Study 9649989 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.05 mg
Number of subjects: 80
Study 9649989 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.10 mg
Number of subjects: 80
Study 9649989 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.15 mg
Number of subjects: 80
Study 9649989 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.20 mg
Number of subjects: 80
Study 7853676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 20 mg/kg administered via intravenous bolus injection or 30‐minute intravenous drip infusion 3 times daily for 3‐11 days
Number of subjects: 13
Study 7853676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 13
Study 7853676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) 20 mg/kg
Number of subjects: 13
Study 2688077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment techniques for RA trials
Number of subjects: 0
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-for-age z-score (LAZ) at birth
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔLAZ from 6 to 18 months
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 18 months
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔLAZ during 0-6 months
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔLAZ from 18 months to 4-6 years
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 6 months
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 4-6 years
Number of subjects: 710
Study 31042813 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor and social-emotional development
Number of subjects: 710
Study 29596014 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT) for 3 months
Number of subjects: 50
Study 29596014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, CON)
Number of subjects: 50
Study 29596014 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 50
Study 26056119 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg weekly + placebo-IV every four weeks
Number of subjects: 1262
Study 26056119 — intervention group
Group type: COMPARATOR
Intervention: TCZ-IV 8 mg/kg every four weeks + placebo-SC weekly
Number of subjects: 1262
Study 26056119 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC
Number of subjects: 1262
Study 26056119 — intervention group
Group type: COMPARATOR
Intervention: TCZ-IV
Number of subjects: 1262
Study 26056119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who switched formulations
Number of subjects: 1262
Study 26056119 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1262
Study 24834511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole extended release (ER)
Number of subjects: 1055
Study 24834511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole immediate release (IR)
Number of subjects: 1055
Study 24834511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole ER
Number of subjects: 1055
Study 23342783 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilicus moxibustion therapy plus Jingui Shenqi Pill (8 pills, 3 times a day)
Number of subjects: 60
Study 23342783 — intervention group
Group type: COMPARATOR
Intervention: Jingui Shenqi Pill (8 pills, 3 times a day)
Number of subjects: 60
Study 20177405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 0
Study 20177405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing second-generation trials
Number of subjects: 0
Study 20177405 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation trials
Number of subjects: 0
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: Procera AllCeram (PA)
Number of subjects: 48
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hot-pressed ceramic (EC)
Number of subjects: 48
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic
Number of subjects: 48
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: All systems
Number of subjects: 48
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic and experimental systems
Number of subjects: 48
Study 18548965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel opposing metal-ceramic and experimental crowns
Number of subjects: 48
Study 16043683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 5 to 40 mg/d
Number of subjects: 12557
Study 11377599 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², day 1) and cisplatin (80 mg/m², day 2)
Number of subjects: 441
Study 11377599 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1100 mg/m², days 1 and 8) and docetaxel (100 mg/m², day 8)
Number of subjects: 441
Study 9203010 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual flash stimuli
Number of subjects: 10
Study 9203010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory non‐target oddball stimuli (P3 experiment)
Number of subjects: 10
Study 7968075 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation (inpatient for 8 weeks and outpatient for 16 weeks)
Number of subjects: 89
Study 7968075 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Number of subjects: 89
Study 2886143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 4
Study 2886143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 4
Study 2529776 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH) infusion at 0.47 pmol.kg‐1.min‐1 for 2.5 hours
Number of subjects: 7
Study 2529776 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 7
Study 31729189 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib
Number of subjects: 740
Study 31669188 — intervention group
Group type: EXPERIMENTAL
Intervention: PA and diet intervention
Number of subjects: 149
Study 31669188 — intervention group
Group type: EXPERIMENTAL
Intervention: PA only intervention
Number of subjects: 149
Study 31669188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only intervention
Number of subjects: 149
Study 31669188 — intervention group
Group type: COMPARATOR
Intervention: Standard care (1 visit)
Number of subjects: 149
Study 28011387 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intensive non-surgical periodontal treatment
Number of subjects: 46
Study 28011387 — intervention group
Group type: COMPARATOR
Intervention: Rescue treatment with delayed intensive treatment
Number of subjects: 46
Study 25195169 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg, maximum 100 mg)
Number of subjects: 17
Study 25195169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 17
Study 22310483 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational Coordination
Number of subjects: 283
Study 22310483 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational Coordination and Reciprocal Learning
Number of subjects: 283
Study 22310483 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Learning
Number of subjects: 283
Study 22310483 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Medical Record presence
Number of subjects: 283
Study 21507295 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α treatment (1.0 ng/mL)
Number of subjects: 16
Study 21507295 — intervention group
Group type: COMPARATOR
Intervention: Untreated FS group
Number of subjects: 16
Study 21507295 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α treatment
Number of subjects: 16
Study 19128956 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection (APR)
Number of subjects: 0
Study 17105853 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etanercept (ETN)
Number of subjects: 0
Study 17105853 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg etanercept (ETN)
Number of subjects: 0
Study 17105853 — intervention group
Group type: COMPARATOR
Intervention: etanercept (ETN)
Number of subjects: 0
Study 17105853 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study 15629872 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 35
Study 15629872 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine 8 mg/day
Number of subjects: 35
Study 11163781 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone, olanzapine, quetiapine)
Number of subjects: 9
Study 9778755 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 100
Study 9778755 — intervention group
Group type: COMPARATOR
Intervention: Rimantadine
Number of subjects: 100
Study 9778755 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 100
Study 7880555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mailed reminder
Number of subjects: 0
Study 7880555 — intervention group
Group type: COMPARATOR
Intervention: Mailed reminder plus incentive
Number of subjects: 0
Study 7880555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 0
Study 7880555 — intervention group
Group type: COMPARATOR
Intervention: Phoned reminder
Number of subjects: 0
Study 7880555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder on physician's letterhead
Number of subjects: 0
Study 7880555 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 0
Study 3206383 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (2.5-10 pmol kg-1 min-1)
Number of subjects: 6
Study 3206383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study 30653856 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (280 mL/d for 8 days)
Number of subjects: 12
Study 30653856 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (acute and chronic)
Number of subjects: 12
Study 30653856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 28223259 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AED) administered from 4 days before surgery until 1 month after surgery
Number of subjects: 320
Study 25060406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100 to 1600 mcg) during a 26-day open-label titration period
Number of subjects: 130
Study 25060406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Number of subjects: 130
Study 23098672 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 29
Study 23098672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22082789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystocele plication during transvaginal repair
Number of subjects: 22
Study 22082789 — intervention group
Group type: COMPARATOR
Intervention: No cystocele plication during transvaginal repair
Number of subjects: 22
Study 19934866 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (phosphodiesterase 3 inhibitor)
Number of subjects: 34
Study 19934866 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 34
Study 16546596 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade with naltrexone
Number of subjects: 16